Observational studyJournal of ovarian research2026
Real-world data of PARP inhibitors in first-line maintenance for BRCA-mutated or HRD-positive advanced ovarian cancer: a multicentre retrospective study from India.
Observational study in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Poly(ADP-ribose) polymerase inhibitor maintenance therapy in ovarian cancer: a single-center retrospective study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as a significant advancement in the maintenance treatment of advanced High-Grade Serous Ovarian Cancer (HGSOC), particularly in patients with BRCA mutations or Homologous Recombination Deficiency (HRD). While randomized trials have demonstrated their efficacy, real-world evidence from low- and middle-income countries (LMIC) like India remains scarce. This retrospective observational multicentre study aimed to assess the safety and effectiveness of first-line maintenance therapy with Olaparib or Rucaparib in Indian patients with BRCA-mutated (BRCAmut) or HRD-positive (HRD+) advanced HGSOC.
resultsThe study evaluated data from 46 patients treated between May 2019 and December 2022 across six oncology centres under the BIRAC-supported Network of Oncology Clinical Trials of India. The median age was 50.5 years, with all having HGS histopathology. Stage III disease was present in 32(69.6%), and 12(26.1%) had a family history of cancer. Median turnaround time for gBRCA and HRD investigation was 18 and 20.5 days, respectively. BRCA1mut were seen in 30(65.2%), BRCA2 in 5(10.9%), and non-BRCA HRD + in 11(23.9%). Olaparib was given to 27(58.7%) and Rucaparib to 19(41.3%). At a median follow-up of 22.5 months (range 18–53), the median PFS was not reached. The 12 and 18-month PFS rates were 97.8% and 86.9%, respectively. No significant difference in mPFS was found between the two drugs or between BRCAmut and BRCA-wild HRD+ patients (NR vs. 29 months, p = 0.219) groups. Dose reductions were made in 18(39.1%) of patients due to toxicity [N = 9(50%)] or cost [N = 9(50%)], with no observed impact on PFS between the standard dose and the reduced dose. The major prevalent grade ≥ 3 toxicities comprised anaemia (13%), fatigue (6.5%), and thrombocytopenia (2.2%).
conclusionDespite limitations of a retrospective design, this study supports the clinical efficacy and tolerability of PARPi in LMIC, with efficacy and toxicity outcomes comparable to global trial data. There were no statistically significant differences observed between Olaparib and Rucaparib, standard and reduced doses, or BRCAmut and HRD+ patients. This study supports the feasibility of incorporating PARPi into frontline maintenance therapy for advanced HGSOC in resource-limited environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.